🔥 Hot Today in Peptide Research

🔥🔥🔥

Report: plans would allow temporary sale of some restricted peptides

Photo: Danka & Peter / StockSnap (CC0) / own upload

The Washington Post reported on 7 October that the administration is crafting plans that would allow the temporary sale of certain previously restricted peptides while federal health officials work out new regulations for the products, citing two people familiar with the matter. The newspaper also noted that FDA scientists and some medical experts have raised concerns about increasing access to certain peptides. The report describes plans still being drawn up; it is not a published FDA notice or rule.

For research-community awareness only. Not legal advice.

🔥🔥

Tunable glycine chemistry singles out Staphylococcus aureus

Photo: Vidsplay / StockSnap (CC0) / own upload

Researchers at IISER Bhopal and collaborating institutes reported in Nature Communications on 5 October an electronically tunable chemical method that selectively modifies N-terminal glycine. Because S. aureus carries a pentaglycine signature in its cell wall, the method allowed species-specific detection of the bacterium and its resistant strains, and labelled it in fruit flies and in mouse infection models. The authors also report inhibition of clinical strains and biofilms in laboratory tests; the work is preclinical.

Read the Full Update

🔥🔥

Peptide coatings tune lipid nanoparticles for mRNA delivery

Photo: asim alnamat / StockSnap (CC0) / own upload

A Tianjin University team reported in Biomacromolecules, published online on 6 October, a way to modify lipid nanoparticles after formulation by coating them with modular multifunctional peptides through physical assembly. In cell experiments the coatings increased cellular uptake, endosomal escape and mRNA translation, and in animal experiments optimised coatings improved mRNA delivery across several LNP formulations. The results are preclinical.

Read the Full Update

🔥

Machine-learning screen finds a polypeptide that dampens TLR9 signalling

Photo: Vidsplay / StockSnap (CC0) / own upload

The Journal of the American Chemical Society published on 7 October a study from researchers in China, including Peking University, that combined high-throughput synthesis and screening with machine-learning-assisted optimisation of random hybrid polypeptides. The lead polypeptide, IDP-IMP, suppressed CpG DNA–TLR9 signalling with limited cytotoxicity through moderate, multivalent interactions rather than strong binding, and lowered inflammation and joint pathology in a rat arthritis model. The work is preclinical.

🔥

Aragen opens a peptide and ADC platform in Hyderabad

Photo: Mateusz Dach / StockSnap (CC0) / own upload

ETPharma reported on 6 October that Aragen Life Sciences has brought into operation Aragen OneHP, an integrated development and manufacturing platform for peptides and antibody-drug conjugates at its Nacharam campus in Hyderabad, India. The platform adds capabilities for highly potent molecules and an active-ingredient manufacturing line with an annual capacity of 500 to 600 kg.

Read the Full Update

🔥

Ofichem to acquire New York CDMO Kinentia Biosciences

Photo: Michal Parzuchowski / StockSnap (CC0) / own upload

Contract Pharma reported on 7 October that Ofichem has agreed to acquire Kinentia Biosciences, a drug-substance contract manufacturer in Rensselaer, New York. According to the report, the deal adds expertise in small peptides, polysaccharides and complex new chemical entities, and after completion Ofichem's drug-substance business will operate across New York, Ter Apel in the Netherlands and Uppsala in Sweden.

Read the Full Update

🔥🔥🔥

Peptide 'bait' quiets pain-signalling neurons in mouse models

Photo: Jeremy Thomas / StockSnap (CC0) / own upload

Boston Children's Hospital reported on 6 October on a study in Cell Reports Medicine showing that the sodium channel NaV1.8 in pain-sensing neurons relies on the scaffolding protein ankyrin-G (Ank3) to sustain the heightened activity seen in pathological pain. A short lipidated peptide (SLiP) that disrupts this interaction lowered NaV1.8 levels in the cell membrane and reduced pain-like behaviours in mouse models, while acute protective pain was spared. The work is preclinical, and the intellectual property has been licensed to a Boston biotechnology company.

Read the Full Update

🔥🔥

Catalytic ring closure builds atropisomeric cyclic peptides

Photo: Altered Reality / StockSnap (CC0) / own upload

IOCB Prague reported on 5 October on a paper in Angewandte Chemie describing a catalytic intramolecular SNAr macrocyclization in which a fluoride catalyst works with an organosilane to form sterically hindered carbon–nitrogen bonds. The method closed linear precursors directly into strained medium-sized rings and macrocycles, and with tryptophan-containing peptides it gave structurally diverse 'atropopeptides' inspired by natural RiPPs. The institute says the new cyclic peptides will next go into bioactivity screening.

Read the Full Update

🔥🔥

SK pharmteco plans a $200M+ US build-out that includes peptides

Photo: Willian Was / StockSnap (CC0) / own upload

BioSpectrum Asia reported on 6 October that SK pharmteco, a subsidiary of South Korea's SK Inc., plans a five-year investment of more than $200 million in its US development and manufacturing infrastructure for small molecules and peptides. The plan includes new development laboratories, new GMP kilo-scale peptide capacity scheduled to be operational in late 2026 alongside advanced liquid chromatography, new manufacturing suites and about 100 long-term US jobs.

Read the Full Update

🔥

CordenPharma adds peptide synthesis at its South Carolina site

Photo: Tommy Lisbin / StockSnap (CC0) / own upload

WJBF reported, in a story updated on 5 October, that CordenPharma is expanding its Aiken County, South Carolina site, previously operated by AmbioPharm, to add peptide synthesis to the purification and quality-control work already done there, so customers can go from synthesis through purification at one location. The company expects more than 200 new jobs, a larger hiring push from the third quarter of 2027, and the expansion to be operational in 2027.

Read the Full Update

🔥

Computer search for tetrapeptide catalysts gets under way in Texas

Photo: Vidsplay / StockSnap (CC0) / own upload

Southwest Research Institute said on 6 October that it will work with The University of Texas at San Antonio to identify tetrapeptide catalysts using SwRI's Rhodium molecular docking platform, the first time the platform will be used to find catalysts rather than drug candidates. SwRI will supply computational data and a list of candidate peptide catalysts, which UT San Antonio researchers will then test and validate in their laboratories. The aim is more efficient synthesis of organic molecules; the project itself will not advance any medicine.

🔥

Engineered bacterial nanomachine carries antimicrobial peptides into infected immune cells

Photo: Bango Renders / StockSnap (CC0) / own upload

BioCentury reported on 6 October on a study from the Chinese Academy of Medical Sciences and Peking Union Medical College in which researchers engineered a bacterial contractile nanomachine (an eCIS derived from the Photorhabdus virulence cassette) to carry mycobacteriophage-derived antimicrobial peptides and bind the CD11b receptor on alveolar macrophages. The system inhibited intracellular mycobacteria in lab tests, including drug-sensitive and isoniazid-resistant M. tuberculosis, and lowered lung bacterial burden by more than tenfold in infected mice.

🔥🔥🔥

VA peptide study bill reaches mainstream coverage

Photo: The Lazy Artist Gallery / StockSnap (CC0) / own upload

Military.com reported on 5 October on the PEPTIDES for Veterans Act (H.R. 10212), a House bill that would direct the Department of Veterans Affairs to review existing peptide regulations and guidance and report to Congress within 180 days, then run an 18-month study of peptide-based therapies. According to the bill text as reported, a pilot with volunteer participants would follow only if the study's findings support it. The bill was introduced on 1 September, referred to the House Veterans' Affairs health subcommittee on 8 September and has not advanced beyond introduction; it does not change the legal status of any peptide.

Read the Full Update

For research-community awareness only. Not legal advice.

🔥🔥

Designed membrane proteins dial down an immune receptor in cell models

Photo: Bonnie Moreland / StockSnap (CC0) / own upload

Technology Networks reported on 5 October on a Scripps Research study in PNAS in which computationally designed proteins that sit inside the cell membrane associated with Toll-like receptor 4 (TLR4). Eight of nine designs showed signs of binding in a light-based proximity assay, and one, Design-6, substantially reduced NF-κB signalling in cultured HEK cells. The authors note the work used a convenience cell line and still needs confirming in more relevant cell types.

Read the Full Update

🔥🔥

Peptide CDMO tender closes 12 October

Photo: Altered Reality / StockSnap (CC0) / own upload

BSR reported on 4 October that the main acceptance period for Samsung Biologics' all-cash offer for Swiss peptide manufacturer PolyPeptide Group, valued at about CHF 1.46 billion, closes at 4 p.m. Swiss time on 12 October, with completion targeted for the end of 2026. The report notes that metabolic peptides now make up about 68% of PolyPeptide's revenue and that new large-scale solid-phase synthesis capacity typically takes 18 to 36 months to build, which keeps capacity tight for smaller research and development batches.

Read the Full Update

🔥

New chemistry builds bicyclic peptide libraries on phage

Photo: HD Wallpapers / StockSnap (CC0) / own upload

A Texas A&M team reported PReP-Bicyc in Nature Communications on 3 October, an additive-free method that turns phage-displayed peptide libraries into bicyclic peptides using a purpose-designed linker, 4,6-dichloropyrimidine-2-carbonitrile, under mild conditions that keep the phage viable. Screening against the protein PD-1 gave sub-micromolar bicyclic ligands, the best with a dissociation constant of about 400 nM, that selectively labelled PD-1-expressing cells in the lab.

Read the Full Update

🔥

Protein language model flags peptide hormones with high accuracy

Photo: Bango Renders / StockSnap (CC0) / own upload

Scienmag reported on 4 October on pLM-HP, a model published in the Journal of Advanced Research that combines the ESM2 protein language model with a bidirectional LSTM to predict whether a short peptide sequence is a hormone. On an independent test set it reached a balanced accuracy of 95.64% and an AUC of 0.991, and a mid-sized ESM2 variant outperformed the largest one. The authors note the model uses sequence only, without structural context.

Read the Full Update

🔥🔥

FDA advisers backed six peptides in July. None is on the compounding list yet

Photo: HD Wallpapers / StockSnap (CC0) / own upload

More than ten weeks after the vote, the federal list that pharmacies compound from still contains no peptides.

An FDA advisory committee voted on 23–24 July 2026 to recommend adding BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon to the Section 503A bulks list, even though FDA's own briefing documents proposed adding none of them. A dated status review published on 3 October found that none has been added: the final list in 21 CFR 216.23 still names six substances, and none is a peptide. Adding any of them would take a proposed rule, a comment period and a final rule, and a committee vote is not FDA approval.

Why it's hot: The 3 October review is the newest dated status check on a decision still pending.

Read the Full Update

Research-community awareness only — not legal advice. For research use only. Not for human or veterinary use. Not a drug, food, or cosmetic.

🔥🔥

FDA's import alert spells out what proof of peptide API quality looks like

Photo: Bob Richards / StockSnap (CC0) / own upload

FDA can now hold GLP-1-class bulk ingredients at the border, and the alert lists the documents a manufacturer needs to get off that list.

FDA's revised Import Alert 66-80, published 21 September 2026, lets its field staff detain imported GLP-1 receptor agonist bulk drug substances without physical examination unless the manufacturer and product are on the alert's Green List. FDA says 21% of the 48 GLP-1 API sites it evaluated were noncompliant with manufacturing requirements or did not answer records requests in time. To be considered for the Green List, the alert asks for evidence such as certificates of analysis for the last ten lots, release specifications covering impurities, potency and microbial attributes, stability protocols and validated test methods.

Why it's hot: "fda import alert 66-80" now appears in Google's autocomplete.

Read the Full Update

Research-community awareness only — not legal advice.

🔥🔥🔥

Public-health experts weigh in on the social-media peptide wave

Photo: The Lazy Artist Gallery / StockSnap (CC0) / own upload

Harvard T.H. Chan School of Public Health published a Q&A on 1 October with Professor S. Bryn Austin about the peptides now being promoted by influencers, including BPC-157, TB-500, MOTS-c, CJC-1295 and ipamorelin. She said many have had little or no rigorous clinical testing and are not FDA-approved, and that with gray-market and so-called "research chemical" sellers nobody can be sure what a vial actually contains. For laboratory buyers, the takeaway is that batch-level identity and purity data matter most.

For research-community awareness only. Not legal advice. For research use only. Not for human or veterinary use. Not a drug, food, or cosmetic.

BioLabs Research has no affiliation with, and no endorsement from, any person named. Source: Harvard T.H. Chan School of Public Health

🔥🔥

Phase 3 data published for an investigational incretin-class compound

Photo: HD Wallpapers / StockSnap (CC0) / own upload

The BMJ reported on 1 October on newly published phase 3 trial data for an investigational incretin-class compound that has not been approved by any regulatory agency. The BMJ also pointed to growing concern about unapproved products of this class sold online, and the UK MHRA warned this summer against "the online hype" around it.

For research-community awareness only. Not legal advice.

🔥🔥

FDA posts nationwide recall of compounded glutathione over endotoxin

Photo: Build Tier List / StockSnap (CC0) / own upload

FDA posted a company announcement on 1 October in which a Texas 503A compounding pharmacy is voluntarily recalling lots of compounded glutathione, a naturally occurring tripeptide, because of potentially elevated endotoxin levels. The lots were distributed nationwide between 26 June and 21 September 2026. The firm reported two emergency-care cases after the product was given by a route it was not formulated for; in research settings, endotoxin is a key quality attribute for peptide materials, because it can trigger inflammatory signalling in cell assays that may be mistaken for a compound effect.

For research-community awareness only. Not legal advice.

🔥🔥

House bill would direct the VA to study peptides for veterans

Photo: Aziz Acharki / StockSnap (CC0) / own upload

Stars and Stripes reported on 28 September that Rep. Nancy Mace has introduced the PEPTIDES for Veterans Act, which would direct the Department of Veterans Affairs to run an 18-month study of the safety and efficacy of peptides for veterans with service-connected conditions. According to the report, the VA would first review current peptide regulations and give Congress its official definitions of "peptide" and "peptide-based therapy", and a five-year pilot would follow only if the initial findings are positive. The bill has been referred to the House Veterans' Affairs health subcommittee.

For research-community awareness only. Not legal advice.

BioLabs Research has no affiliation with, and no endorsement from, any person named. Source: Stars and Stripes

🔥

Comment window closes on FDA's revised generic peptide guidances

Photo: FreePhotos / StockSnap (CC0) / own upload

The Federal Register notice published on 29 July set 28 September 2026 as the deadline for comments on FDA's revised draft product-specific guidances for generic peptide drugs. These guidances set out how generic manufacturers should show bioequivalence to an approved reference product, and the notice lists active ingredients of several peptide drugs, including incretin-class compounds, teriparatide, glucagon and calcitonin salmon. According to the notice, FDA considers comments received by the deadline before it begins work on the final versions.

For research-community awareness only. Not legal advice.